The SYT16 antibody targets Synaptotagmin 16 (SYT16), a member of the synaptotagmin family of membrane-trafficking proteins. SYT16 is characterized by its N-terminal transmembrane domain and C-terminal tandem C2 domains, which are implicated in calcium-dependent membrane interactions. While the functional roles of SYT16 remain less defined compared to well-studied isoforms like SYT1 (critical for synaptic vesicle exocytosis), emerging research suggests its involvement in secretory pathways, particularly in non-neuronal tissues. SYT16 is expressed in the brain, pancreas, and other organs, with studies linking it to Golgi-associated vesicle transport, hormone secretion, and cellular stress responses. Its potential role in diseases, such as cancer or neurological disorders, is under investigation, though mechanistic insights are limited.
SYT16 antibodies are primarily used as research tools to detect protein expression, localization, and interaction partners via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Commercial SYT16 antibodies are often developed in rabbits or mice, with validation in specific cell lines or tissues. However, users should verify antibody specificity due to possible cross-reactivity with other synaptotagmins or isoforms. Recent studies utilizing SYT16 antibodies have explored its regulatory effects on secretion in pancreatic β-cells and its dysregulation in tumors, highlighting its emerging relevance in cellular physiology and pathology.